Depression is a common psychiatric disorder with heavy economic and social burdens. Searching new agents with better antidepressant-like activities is of great significance for depression therapy. Tauroursodeoxycholic acid (TUDCA), a clinical drug for gallstone treatment, possesses neuroprotective effects in different brain disorders. However, whether it affects depression remains unclear. We addressed this issue by evaluating the effect of TUDCA on depression induced by chronic unpredictable stress (CUS). Results showed that TUDCA treatment at 200 but not 100 mg/kg prevented the 5 weeks of CUS-induced increases in the immobile time of C57BL6/J mice in the experiments of forced swimming test and tail suspension test as well as the CUS-induced decrease in sucrose intake and crossing numbers in the open-field test, and did not enhance the antidepressant-like effect of fluoxetine. Attenuation of neuroinflammation may be involved in the antidepressant-like effect of TUDCA, as TUDCA treatment (200 mg/kg) normalized the levels of tumor necrosis factor-a and interleukin-6 in both hippocampus and prefrontal cortex. The increases in inflammasome and microglial activation markers, including interleukin-b, nod-like receptor protein 3, and Iba-1, in CUS-treated mice were reduced by TUDCA treatment (200 mg/kg). TUDCA treatment (200 mg/kg) also normalized the changes in markers reflecting the oxidative-nitrosative and endoplasmic reticulum (ER) stress induced by CUS, such as nitric oxide, reduced glutathione, malondialdehyde, glucose-regulated protein 78, and C/EBP homologous protein. These results revealed that TUDCA improved the CUS-induced depression-like behaviors likely through attenuation of neuroinflammation, oxido-nitrosative, and ER stress. 
A B S T R A C T
Depression is a common psychiatric disorder with heavy economic and social burdens. Searching new agents with better antidepressant-like activities is of great significance for depression therapy. Tauroursodeoxycholic acid (TUDCA), a clinical drug for gallstone treatment, possesses neuroprotective effects in different brain disorders. However, whether it affects depression remains unclear. We addressed this issue by evaluating the effect of TUDCA on depression induced by chronic unpredictable stress (CUS). Results showed that TUDCA treatment at 200 but not 100 mg/kg prevented the 5 weeks of CUS-induced increases in the immobile time of C57BL6/J mice in the experiments of forced swimming test and tail suspension test as well as the CUS-induced decrease in sucrose intake and crossing numbers in the open-field test, and did not enhance the antidepressant-like effect of fluoxetine. Attenuation of neuroinflammation may be involved in the antidepressant-like effect of TUDCA, as TUDCA treatment (200 mg/kg) normalized the levels of tumor necrosis factor-a and interleukin-6 in both hippocampus and prefrontal cortex. The increases in inflammasome and microglial activation markers, including interleukin-b, nod-like receptor protein 3, and Iba-1, in CUS-treated mice were reduced by TUDCA treatment (200 mg/kg). TUDCA treatment (200 mg/kg) also normalized the changes in markers reflecting the oxidative-nitrosative and endoplasmic reticulum (ER) stress induced by CUS, such as nitric oxide, reduced glutathione, malondialdehyde, glucose-regulated protein 78, and C/EBP homologous protein. These results revealed that TUDCA improved the CUS-induced depression-like behaviors likely through attenuation of neuroinflammation, oxido-nitrosative, and ER stress.
I N T R O D U C T I O N
Major depression is one of the most common mental diseases in the worldwide with different degrees of sadness feelings. In clinic, several drugs such as selective serotonin reuptake inhibitors and serotonin receptor transporter inhibitors have been developed to treat depression [1, 2] . However, as only about one-third of depressed patients are sensitive to these antidepressants and approximately two-third of patients' response only after several weeks of treatment [3] , it is urgent to search new antidepressants with better therapeutic efficiencies.
The neuroinflammatory response triggered by microglial overactivation is considered an important factor mediating the formation and/or development of depression. Lipopolysaccharide (LPS) administration has been shown to induce microglial overactivation and trigger depression-like behaviors in animals [4, 5] , which can be attenuated by microglial inhibition [6, 7] . Traditional antidepressants and electroconvulsive therapy are reported to modulate microglial structures and functions, thereby preventing depression formation [8] .
Other studies show that direct administration of mice with tumor necrosis factor-a (TNF-a), and interleukin-6 (IL-6) or interleukin-b (IL-1b) also induces typical depression-like behaviors [9] [10] [11] . Recently, an IL-1b-producing structure, inflammasome, has been confirmed a sensor for depression-inducing stress [12] . Deletion of the gene of NLR family pyrin domain containing 3 (NLRP3) may impair the depression-associated behaviors and neuroinflammatory responses [13] . Mechanistically, the pro-inflammatory response in the brain mediates the formation and/or development of depression likely through generation of oxidonitrosative stress [14, 15] . Suppressing the brain proinflammatory response along with oxido-nitrosative stress may be a promising strategy for depression therapy.
Endoplasmic reticulum (ER) stress is a pathophysiological event characterized by misfolded or unfolded protein accumulation in ER [16, 17] . Under physiological settings, ER stress helps manage unfolded/misfolded proteins via promotion of protein degradation or increase in ER chaperones such as glucose-regulated protein 78 (GRP78) [18] . Upon prolonged stress stimulation, the C/EBP homologous protein (CHOP) triggered by ER stress will be increased and promote cell death [19] . Increasing studies report that ER stress can mediate the pathogenesis of depression, and its suppression may contribute to the antidepressant-like effects of different antidepressants [20] [21] [22] . Searching effective compounds targeting ER stress may be beneficial for depression therapy.
Tauroursodeoxycholic acid (TUDCA), a kind of bile acids, because of its neuroprotective effects in several different brain disorders such as Alzheimer's disease and Huntington's disease, is attracting more and more attentions in recent years [23, 24] . The neuroprotective effects of TUDCA may be associated with its inhibitory effect on microglial overactivation. For example, through specifically reduction in microglial reactivity, TUDCA can inhibit microglial migration in mice hippocampus [25] and prevent retinal degeneration [26] . TUDCA is also regarded as an inhibitor of ER stress, whose inhibition has been well-documented to mediate the protective effects of TUDCA on diabetes, obesity, and major depression [27] [28] [29] . Within these contexts, we hypothesize that TUDCA may have antidepressantlike activities, and attenuation of neuroinflammation, oxido-nitrosative stress, or ER stress may be a core mechanism for the antidepressant-like effect of TUDCA.
M A T E R I A L A N D M E T H O D S

Animals
A total of 8-to 10-week-old male C57BL/6J mice were housed five per cage under standard conditions (12-h light/dark cycle; lights on from 07:00 to 19:00; 23 AE 1°C ambient temperature; 55 AE 10% relative humidity) for 1 week with free access to food and water. Each experimental group consisted of 10 mice. Behavioral experiments were carried out from the 9:00 am to 5:00 pm. Animal experiments were conducted in accordance with internationally accepted guidelines for the use of animals in toxicology as adopted by the Society of Toxicology in 1999) and approved by the University Animal Ethics Committee of Nantong University (Permit Number: 2110836).
Materials
Tauroursodeoxycholic acid and fluoxetine were purchased from MedChem Express (Princeton, NJ, USA). The dosage of fluoxetine in this study was chosen as previous studies [4, 30] . Fluoxetine and TUDCA were administered intraperitoneally (i.p.) in a volume of 10 mL/kg. The antibodies against Iba-1 and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) were purchased from Abcam (Cambridge, MA, USA) and Cell Signaling Technology (Beverly, MA, USA), respectively.
Tail suspension test and forced swimming test
The tail suspension test (TST) and forced swimming test (FST) were performed according to the method of Steru et al. [31] and Porsolt et al. [32] , respectively, and were summarized in Figure 1 . Briefly, 2 h after the last injection, the experimental mice were individually placed in a clear glass cylinder (height 25 cm, diameter 10 cm) filled to 10 cm with water at 25 AE 1°C for 6 min, or suspended 50 cm above the floor for 6 min by adhesive tape placed approximately 1 cm from the tip of the tail. The duration of immobility was recorded during the last 4 min by an investigator blind to the study. In the FST, the immobile time was defined as the time spent by the mouse floating in the water without struggling and making only those movements necessary to keep its head above the water. In the TST, the mice were considered immobile only when they hung passively and were completely motionless, and any mice that did climb their tails were removed from the experimental analysis. Chronic unpredictable stress and sucrose preference test The chronic unpredictable stress (CUS) [33] , consisting of daily exposure to two of the following stressors in a random order over a 5-week period, cage shaking for 1 h, lights on during the entire night (12 h), placement in 4°C cold room for 1 h, mild restraint (in small cages) for 2 h, 45°C cage tilt for 14 h, lights off for 3 h during the daylight phase, wet cage for 14 h, flashing light for 6 h, noise in the room for 3 h, and water deprivation for 12 h during the dark period, was used to induce chronic stress in C57BL/6J mice. The sucrose preference test (SPT) was performed at day 36 ( Figure 1) . The experimental mice were given the choice to drink from two bottles in individual cages, one with 1% sucrose solution and the other with water [4]. All were acclimatized for 2 days to two-bottle choice conditions, and the position of two bottles was changed every 6 h to prevent possible effects of side preference in drinking behavior. The mice were then deprived of food and water for 24 h, and on day 39, the mice were exposed to preweighed bottles for 1 h with their position interchanged. Sucrose preference was calculated as a percentage of the consumed sucrose solution relative to the total amount of liquid intake.
Open-field test
Western blot
This experiment was performed according to some previous studies [34] [35] [36] with some modifications. Briefly, the brain tissues were lysed on ice for 30 min in the following lyses buffer: 50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 100 mM NaCl, 20 mM NaF, 3 mM Na 3 VO 4 , 1 mM PMSF with 1% NP-40, and protease inhibitor cocktail. The lysates were then centrifuged at 12 000 g for 15 min, and their supernatants were harvested. After being denatured, 20-30 lg of proteins was separated on 10% SDS/PAGE gels and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). After being blocked with 5% nonfat dried milk powder/Tris-buffered saline Tween-20 (TBST) for 1 h, the nitrocellulose membrane was probed with primary antibodies against Iba-1 (1 : 500) or GAPDH (1 : 1000) overnight at 4°C. Primary antibodies were removed by washing the membranes 3 times in TBST. Membranes were further incubated for 2 h at room temperature with IRDye 680-labeled and species-appropriate secondary antibody (1 : 3000-1 : 5000). The immunoblots were visualized by scanning using the Odyssey CLx Western blot detection system. The band density was quantified using ImageJ software (U.S. National Institutes of Health, Bethesda, MD, USA).
Measurement of malondialdehyde levels
Malondialdehyde (MDA) content was determined quantitatively, according to one of our previous studies [4] . Briefly, 100 lL of sample was added to 100 lL of 8.1% sodium dodecyl sulfate, 0.75 mL of 20% acetic acid solution (pH 3.4) and 750 lL of 0.8% thiobarbituric acid. The mixture was made up to 3 mL with distilled water. The resultant mixture was then heated on a water bath at 95°C for 60 min, cooled, and then centrifuged at 12 000 g for 10 min. Supernatant was collected, and the absorbance was taken at 532 nm. Results were expressed as lM/g of tissue weight.
Measurement of reduced glutathione levels
The reduced glutathione (GSH) content was estimated using the method of Beutler et al. [37] . The supernatants of the homogenate were mixed with trichloroacetic acid (10% w/v) in 1 : 1 ratio and centrifuged at 10 000 g for 10 min at 4°C. The supernatant obtained (500 lL) was mixed with 2 mL of 0.3 M disodium hydrogen phosphate. Thereafter, 250 lL of 0.001 M freshly prepared DTNB [5, 50-dithiobis (2-nitro benzoic acid) dissolved in 1% w/v sodium citrate] was added. The absorbance was taken at 412 nm, and the results were calculated as lg/g of tissues.
NO detection
Total nitrite levels were measured with a Griess reagent kit (Invitrogen, Carlsbad, CA, USA) according to a previous study [38] . The reaction consisted of 20 mL of Griess Reagent, 150 lL of serum or cell supernatants, and 130 lL of de-ionized water. After incubation of the mixture for 30 min at room temperature, nitrite levels were measured at 548 nm using an M2 spectrophotometric microplate reader (Molecular Devices, Carlsbad, CA, USA).
Measurement of brain IL-6, TNF-a, and IL-1b levels
The levels of brain IL-6, TNF-a, and IL-1b were determined according to manufacturer's protocol available with the respective kits (Proteintech, Wuhan, China). Concentrations of IL-6, TNF-a, and IL-1b were expressed as picogram per gram tissues (pg/g tissues).
Measurement of NLRP3, IL-1b, GRP78, and CHOP mRNA levels by real-time PCR Total RNA was extracted from freshly isolated brain tissues using HiPuraA TM Total RNA Miniprep purification kit (HiMedia, Mumbai, India). 1 lg of RNA was diluted in 20 lL of retro-transcription reagent and used to synthesize cDNA with the RevertAid First Strand cDNA synthesis kit (Thermo Fisher Scientific, Mumbai, India). To quantitatively determine gene expression, real-time PCR analysis was performed using QuantiTect SYBR Green PCR 9 Master Mix and the ABI 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instruction, and the housekeeping gene b-actin was used as an internal control. Primers for this experiment were as follows [22, 39, 40] : GRP78, forward 5-GTTTGC TGAGGA AGA-CAAAAAGCTC-3, reverse 5-CACTTCCATA-GAGTTTGCTGATAATTG-3; CHOP, forward 5-GGAG CTGGAAGCCTGGTATGAGG-3, reverse 5-TCCCTGGTCA GGCGCTCGATTTCC-3; NLRP3, forward ATGGCTGTG TGGATCTTTGC, reverse CACGTGTCATTCCACTCTGG; IL-1b, forward 5-CTTCAGGCAGGCAGTATC-3, reverse 5-CAGCAGGTTATCATCATCATC-3; b-actin (housekeeping gene) forward 5-GTCAGAAGGACTCCTATGTG-3 and reverse 5-ACGCAGCTCATTGTAGAAG-3. Gene expression was quantified using the relative standard curve method. Different dilutions of cDNA synthesized from RNA extracted from brain tissues were used to plot the standard curves for genes including GRP78, CHOP, NLRP3, and IL-1b mRNA, which were normalized to b-actin expression and expressed as 2 ÀDDCt .
Statistical analysis
All analyses were performed using SPSS 11.0 software (Chicago, IL, USA) and were presented as mean AE SEM. Differences between mean values were evaluated using two-way analysis of variance (ANOVA), and Bonferroni's post hoc tests were used to assess isolated comparisons. P < 0.05 was considered statistically significant. The change in mice depression-like behaviors was also evaluated in the OFT (Figure 1) . ANOVA revealed significant main effects for CUS treatment [F (1, 72) = 31.25, P < 0.001], drug treatment [F (3, 72) = 7.23, P < 0.001], and CUS 9 drug interaction [F (3, 72) = 7.00, P < 0.001] (Figure 2d) . The mice crossing numbers were markedly reduced by CUS stimulation (Figure 2d , n = 10, P < 0.01 vs. vehicle alone treatment). The fluoxetine (20 mg/kg) or TUDCA (100, 200 mg/kg) alone treatment did not affect the mice crossing numbers in the OFT (Figure 2d) , but 10 days of fluoxetine (20 mg/kg) or TUDCA (200 mg/kg) treatment prevented the decrease in crossing numbers induced by CUS stimulation (Figure 2d , n = 10, P < 0.01 vs. CUS + vehicle).
R E S U L T S
We next examined whether TUDCA could enhance the antidepressant-like effect of fluoxetine. As shown in (Figure 3d) . Post hoc analysis indicated that although both fluoxetine and fluoxetine-TUDCA co-treatment inhibited the mice depression-like behaviors in the FST (Figure 3a , n = 10, P < 0.05 or P < 0.01 vs. CUS + vehicle), TST (Figure 3b , n = 10, P < 0.05 vs. CUS + vehicle), SPT (Figure 3c , n = 10, P < 0.05 vs. CUS + vehicle), and OFT (Figure 3d , n = 10, P < 0.05 or P < 0.01 vs. CUS + vehicle), the mice in the fluoxetine-TUDCA co-treated-group did not show more behavioral improvements in the FST (Figure 3a) , TST (Figure 3b) , SPT (Figure 3c) , and OFT (Figure 3d ). Effect of TUDCA treatment on CUS-induced changes in TNF-a and IL-6 levels in mice hippocampus and prefrontal cortex TNF-a and IL-6 are two important inflammatory mediators, which play critical roles in depression formation [9] . For TNF-a in this experiment, ANOVA revealed significant main effects for CUS treatment Effect of TUDCA treatment on CUS-induced changes in inflammasome markers NLRP3 and IL1b in mice hippocampus and prefrontal cortex The role of inflammasome activation has been confirmed to mediate the pathogenesis of depression [12, 13] . Here, we studied the influence of TUDCA on NLRP3 and IL-1b gene expression. Effect of TUDCA treatment on CUS-induced increase in the expression of Iba-1, a marker for microglial activation The IL-1b is a core cytokine mediating the formation and/or development of depression, and the increased IL-1b may contribute to the production of TNF-a and IL-6 in chronic stress-stimulated brains [9, 10] . As all these reactions mainly occur in microglia, we investigated the activation status of microglia via evaluating the protein expression levels of Iba-1, a classical marker for microglial activation, in mice hippocampus and prefrontal cortex. Data from the Iba-1 detection experiment revealed a significant main effect for TUDCA treatment in both hippocampus [F (2, 12) = 7.10, P < 0.01] (Figure 6a Effect of TUDCA treatment on CUS-induced oxidative and nitrosative stress in mice hippocampus and prefrontal cortex In previous studies, the oxidative and nitrosative stresses have been widely reported to be involved in the pathogenesis of depression [14, 15] . Here, we studied the influence of TUDCA on NO, MDA, and GSH. CUS + vehicle). Data were expressed as mean AE SEM, n = 6, **P < 0.01 vs. vehicle alone treatment, # P < 0.05 vs.
CUS + vehicle. 
D I S C U S S I O N
The present findings indicate that TUDCA, a chemical chaperone, protects the mice against the CUS-induced depression-like behaviors via attenuation of neuroinflammation, oxido-nitrosative stress, and ER stress in mice hippocampus and prefrontal cortex. These findings evidence the potential role of neuroinflammation, oxido-nitrosative stress, and ER stress in depression formation and extend the pharmacological role of TUDCA beyond a metabolic regulator to a potential modulator of depression. In rodents, the FST, TST, and SPT are widely used to evaluate the depression-like behaviors [4, 31, 32] . We showed here that daily injections of TUDCA (10 days) markedly improved the behavioral impairments in CUS-stimulated mice in the FST, TST, SPT, and OFT. The antidepressant-like effect of TUDCA was similar to that of fluoxetine, a classical antidepressant in clinic. However, the TUDCA-fluoxetine co-treatment strategy did not enhance the antidepressant-like effect of fluoxetine, suggesting that TUDCA and fluoxetine suppress depression-like behaviors likely through similar mechanisms. Considering TUDCA is a clinical available drug used to treat cholesterol gallstone [41] , TUDCA may be developed as a new antidepressant in the future. As chronic stress has been widely reported to induce depression-like behaviors via promotion of neuroinflammation in different brain regions such as hippocampus and prefrontal cortex [42] , and direct immunization of mice with pro-inflammatory mediators can trigger typical depression-like behaviors, major depression is now considered a microglial disease [43] . Inhibition of microglia by different agents may provide hopes for depression therapy [4] [5] [6] [7] . Our results report that the increases in TNF-a and IL-6 protein induced by CUS in mice hippocampus and prefrontal cortex were inhibited by 10 days of TUDCA treatment, which are in accordance with some recent studies showing that TUDCA exerts neuroprotective effects likely through inhibition of microglial activation [25, 26] , and indicate that the antidepressant-like effect of TUDCA may be associated with neuroinflammation inhibition. The expressions of two inflammasome markers NLRP3 and IL-1b in CUS-treated mice were also reduced by TUDCA treatment, which appears to be more important than inhibition of TNF-a and IL-6 production by TUDCA. On the one hand, the depression formation has been shown to be dependent on NLRP3 induction, a critical pathophysiological event downstream of neuroinflammation [13] . Inhibition of NLRP3 induction may be more effective in depression therapy than that inhibits the production of proinflammatory cytokines directly. On the other hand, IL-1b, a cytokine produced from NLRP3 and inflammasome activation, is considered a famous molecule mediating the formation and/or development of depression. For example, IL-1b is found to be increased in depressed elderly subjects and directly proportional to the severity of illness [44] . Acutely depressed and previously unmedicated patients have a higher concentration of IL-1b in the cerebrospinal fluid [45] , and the decrease in hippocampal neurogenesis under the influence of IL-1b can be blocked by IL-1b antagonists [46] . It is worth pointing out particularly that TUDCA can reduce the Iba-1 protein expression in CUS-treated hippocampus and prefrontal cortex, suggesting that the inhibition of pro-inflammatory cytokine production by TUDCA may be due to microglial inhibition. In fact, the direct inhibitory role of TUDCA in microglial activation has been reported in previous studies [26, 47] . As the pharmacological role of TUDCA may be mediated by different bile acid receptors or molecules such as Takeda G protein-coupled receptor 5 (TGR5) and transforming growth factor b (TGFb) [25, 47] , the next question that should be answered is that which receptor or molecule mediates the anti-microglial activation effect of TUDCA.
Our results also provide substantial results to evidence the previously observed reports of protection against depression by targeting oxido-nitrosative stress [29] . TUDCA was found to normalize the levels of markers reflecting the status of oxidative-nitrosative stress in CUS-treated mice, including suppression of MDA/nitrite increase and GSH decrease in mice hippocampus and prefrontal cortex. The reduced GSH content indicates the lower antioxidant status, while the increased MDA and nitrite reflects a higher oxidative and nitrosative status [48, 49] . During the neuroinflammatory response, the activated central immune system enhances oxidative-nitrosative stress via production of nitrite, a typical inflammatory molecule bridging neuroinflammation and oxido-nitrosative stress via reaction with reactive oxygen species [50] . As TUDCA can reduce the production of nitrite in both CUS-stimulated hippocampus and prefrontal cortex, we hypothesize that TUDCA alter the oxido-nitrosative status likely through attenuation of nitrite production. This hypothesis should be investigated in future studies. Endoplasmic reticulum is an intracellular organelle, which plays critical roles in disorders associated with inflammation and oxido-nitrosative stress such as diabetes, obesity, cancer, atherosclerosis, and neurodegenerative diseases [51, 52] . During ER stress, two classical chaperones GRP78 and CHOP can be induced substantially. The former chaperone is in charge of ER functioning and UPR initiation [53] , while the latter one promotes cell apoptosis [54] . We found that during CUS exposure the expression levels of GRP78 and CHOP mRNA were increased substantially in mice hippocampus and prefrontal cortex, which were inhibited by 10 days of TUDCA treatment, suggesting that inhibition of ER stress may be an important mechanism for the antidepressant-like effect of TUDCA. Elevated levels of GRP78 and CHOP can leak into the cytoplasm where the pro-inflammatory response and oxido-nitrosative stress may be triggered obviously [55, 56] , and through this mechanism, the ER stress and ER stress-evoked inflammation and oxido-nitrosative stress form a vicious cycle, which ultimately results in neuronal injury and depression formation. This hypothesis is in highly accordance with the finding that TUDCA simultaneously normalizes the pathological changes in markers reflecting high levels of neuroinflammation, oxidonitrosative stress, and ER stress in CUS-stimulated hippocampus and prefrontal cortex, and may also be supported by other evidences involving the role of ER stress in depression formation. For example, disturbance of brain hydrogen sulfide generation has been shown to promote the formation of depression-like behaviors via induction of ER stress [57] . In addition, sodium phenylbutyrate, a well-known inhibitor of ER stress, is reported to abrogate depression-like behaviors induced by chronic restraint stress via attenuation of neuroinflammation, oxido-nitrosative stress, and ER stress [22] . Our results regarding the improvement effects of TUDCA on mice depression-like behaviors further support the role of neuroinflammation, oxido-nitrosative stress, and ER stress in depression formation. Strategies targeting these pathophysiological events may be beneficial for searching new antidepressants.
C O N C L U S I O N
Through evaluation of the effect of TUDCA on mice depression-like behaviors, our results not only strengthen the importance of neuroinflammation, oxido-nitrosative stress, and ER stress in depression formation, but reveal possible mechanisms underlying the regulation effect of TUDCA on depression-like behaviors. As TUDCA is a clinical available drug, intake of TUDCA could be developed as a potential strategy for depression therapy. However, before getting clear conclusions, more assessments, such as evaluation of the antidepressant-like activity of TUDCA in other depression models or patients, should be performed in future studies. 
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